Paradigm, a tech company that aims to integrate clinical trials more broadly into the healthcare system, launched Jan. 27 with a $203 million series A funding round co-led by venture capital firm General Catalyst.
The startup says it's creating a technology-enabled platform to "make clinical trials a care option for all patients." Paradigm also acquired Deep Lens, a company that uses EHR and genomics data to recruit oncology patients for clinical trials.
"By rethinking how clinical trials are conducted and reducing the burden on health systems for participation, they're democratizing access to clinical trials," said Hemant Taneja, CEO and managing director of General Catalyst and board co-chair for Paradigm, in a news release.
Paradigm's board of directors also includes Stephen Klasko, MD, an executive-in-residence at General Catalyst and the former president and CEO of Philadelphia-based Jefferson Health.
The financing round was co-led by Arch Venture Partners and also featured the American Cancer Society's BrightEdge fund.